The pathogenesis of diabetic nephropathy: Focus on microRNAs and proteomics

Journal of Nephrology

Volumn 26, Issue 5, 2013, Pages 811-820

  Conserva, Francesca ^a   Pontrelli, Paola ^a   Accetturo, Matteo ^a   Gesualdo, Loreto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Biomarkers; Diabetic nephropathy; Epigenetics; MicroRNA; Proteomics; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; CYTOKINE; HEXOSAMINE; MICRORNA; POLYOL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; GENETIC MARKER; TRANSCRIPTOME;

BODY FLUID; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DISEASE CLASSIFICATION; EXTRACELLULAR MATRIX; GLOMERULUS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; MESANGIUM CELL; METABOLITE; PATHOGENESIS; PHENOTYPE; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; COMPLICATION; DIABETIC NEPHROPATHIES; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETICS; KIDNEY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; KIDNEY; MICRORNAS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84884656856     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000262     Document Type: Review

References (61)

1. Kanwar YS, Sun L, Xie P, Liu F, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annual Review of Pathology: Mechanisms of Disease. 2011; 6(1): 395-423.
2. Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract. 2008; 82(Suppl 1): S75-S79.
3. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007; 49(2)(Suppl 2): S12-S154.
4. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol. 1993; 3(8): 1458-1466.
5. Carstens SA, Hebert LA, Garancis JC, Piering WF, Lemann J Jr. Rapidly progressive glomerulonephritis superimposed on diabetic glomerulosclerosis: recognition and treatment. JAMA. 1982; 247(10): 1453-1457.
6. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int. 2000; 58(4): 1719-1731.
7. Mazzucco G, Bertani T, Fortunato M, et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis. 2002; 39(4): 713-720.
8. Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. Contrib Nephrol. 2011; 170: 1-7.
9. Brownlee MD. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995; 46(1): 223-234.
10. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001; 27(5 Pt 1): 535-542.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865): 813-820.
12. Kaneto H, Xu G, Song KH, et al. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem. 2001; 276(33): 31099-31104.
13. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol. 2003; 14(8)(Suppl 3): S241-S245.
14. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107(9): 1058-1070.
15. Ha H, Lee HB. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int. 2000; 58(S77): S19-S25.
16. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23(5): 599-622.
17. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 1999; 13(1): 23-30.
18. Sedeek M, Callera G, Montezano A, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2010; 299(6): F1348-F1358.
19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54(6): 1615-1625.
20. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984; 311(2): 89-93.
21. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12): 861-869.
22. Saito T, Saito T, Tamemoto H, et al. Combination therapy of angiotensin converting enzyme inhibitor and angiotensin AT1 receptor antagonist in diabetic nephropathy. Hong Kong Journal of Nephrology. 2007; 9(1): 31-35.
23. Gross ML, El-Shakmak A, Szábó A, et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia. 2003; 46(6): 856-868.
24. Liebau MC, Lang D, Böhm J, et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006; 290(3): F710-F719.
25. Tunçdemir M, Oztürk M. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acta Histochem. 2011; 113(8): 826-832.
26. Möllsten A, Vionnet N, Forsblom C, et al. A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women. Mol Genet Metab. 2011; 103(1): 66-70.
27. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989; 36(4): 626-635.
28. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992; 42(1): 46-55.
29. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994; 93(6): 2431-2437.
30. Mogyorósi A, Ziyadeh FN. GLUT1 and TGF-beta: the link between hyperglycaemia and diabetic nephropathy. Nephrol Dial Transplant. 1999; 14(12): 2827-2829.
31. Mogyorósi A, Kapoor A, Isono M, Kapoor S, Sharma K, Ziyadeh FN. Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy. Nephron. 2000; 86(2): 234-235.
32. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGFbeta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996; 45(4): 522-530.
33. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA. 2000; 97(14): 8015-8020.
34. Russo LM, del Re E, Brown D, Lin HY. Evidence for a role of transforming growth factor (TGF)-t1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-bbtype II receptor. Diabetes. 2007; 56(2): 380-388.
35. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6): 685-700.
36. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004; 22(4): 233-241.
37. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol. 2006; 17(9): 2504-2512.
38. Tang X, Tang G, Özcan S. Role of microRNAs in diabetes. Biochim Biophys Acta. 2008; 1779(11): 697-701.
39. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA. 2007; 104(9): 3432-3437.
40. Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009; 11(7): 881-889.
41. Hata A, Davis BN. Control of microRNA biogenesis by TGFbeta signaling pathway: a novel role of Smads in the nucleus. Cytokine Growth Factor Rev. 2009; 20(5-6): 517-521.
42. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2): 126-139.
43. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 2003; 13(9): 478-483.
44. Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes. 2010; 59(7): 1794-1802.
45. Wang Q, Wang Y, Minto AW, et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 2008; 22(12): 4126-4135.
46. Zhang Z, Peng H, Chen J, et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009; 583(12): 2009-2014.
47. Fu Y, Zhang Y, Wang Z, et al. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol. 2010; 32(6): 581-589
48. Du B, Ma LM, Huang MB, et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 2010; 584(4): 811-816.
49. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem. 2011; 286(13): 11837-11848.
50. Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci. 2006; 100(1): 22-28.
51. Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 expression by TGF-m1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012; 23(2): 252-265.
52. Hennessy E, Clynes M, Jeppesen PB, O'Driscoll L. Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells. Biochem Biophys Res Commun. 2010; 396(2): 457-462.
53. Sun L-L, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM. MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract. 2011; 91(1): 94-100.
54. Bakris, GL, Williams M, Dworkin L, et al. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000: 36(3): 646-661.
55. Otu HH, Can H, Spentzos D, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care. 2007; 30(3): 638-643.
56. Papale M, Di Paolo S, Magistroni R, et al. Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy. Diabetes Care. 2010; 33(11): 2409-2415.
57. Zürbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes. 2012; 61(12): 3304-3313.
58. Wu J, Chen YD, Yu JK, Shi XL, Gu W. Analysis of urinary proteomic patterns for type 2 diabetic nephropathy by ProteinChip. Diabetes Res Clin Pract. 2011; 91(2): 213-219.
59. Jim B, Ghanta M, Qipo A, et al. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS ONE. 2012; 7(5): e36041.
60. Soggiu A, Piras C, Bonizzi L, Hussein HA, Pisanu S, Roncada P. A discovery-phase urine proteomics investigation in type 1 diabetes. Acta Diabetol. 2012; 49(6): 453-464.
61. Merchant ML, Perkins BA, Boratyn GM, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol. 2009; 20(9): 2065-2074.